Drugs / EBP05
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05965167 | May 2023 → Feb 2026 | disease of bone structure, hypoparathyroidism, osteoporosis | Entera Bio Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04003467 | Jun 2019 → Apr 2021 | osteoporosis | Entera Bio Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBP05 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04003467 ↗ |
| Route | Oral | “subjects will be randomly assigned to receive 3 tablets of EBP05 containing 0.5mg hPTH(1-34) orally each day for 6 months” NCT04003467 ↗ |